Side-by-side · Research reference
KPVvsPT-141
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft13/39 cited
BFDA-ApprovedReviewed13/41 cited
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
01Mechanism of Action
Parameter
KPV
PT-141
Primary target
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Pathway
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Downstream effect
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Feedback intact?
No melanocortin receptor binding
—
Origin
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Antibody development
—
—
02Dosage Protocols
Parameter
KPV
PT-141
Standard dose
200–500 mcg / day SQ or oralDalle-Pang 2024
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
Frequency
Daily or 2–3× per week
PRN, max 8 doses / month
Lower / starter dose
100 mcg / day
1 mg (off-label)
Evidence basis
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Duration
4–8 weeks per cycle
PRN; reassess if no benefit after 8 doses
Reconstitution
Bacteriostatic water (SQ form)
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Timing
No specific time; often taken with / before meals (oral)
≥45 min before sexual activity
04Side Effects & Safety
Parameter
KPV
PT-141
Injection site reaction
Mild irritation
Erythema, mild pain
GI symptoms
Rare nausea (oral form)
—
Long-term safety
Limited human data
—
Pregnancy / OB
Avoid — insufficient data
Contraindicated
Flushing
—
Common, transient
Headache
—
Common
Hyperpigmentation (focal)
—
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
Hypertension (transient)
—
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
Cardiovascular disease
—
Use caution; transient BP rise
Absolute Contraindications
KPV
- ·Pregnancy / breastfeeding
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Relative Contraindications
KPV
- ·Active autoimmune disease (theoretical)
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
05Administration Protocol
Parameter
KPV
PT-141
1. Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
2. Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
SQ — abdomen or thigh.
3. Timing
Morning preferred; oral form taken with / before meals.
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
5. Needle
29–31G insulin syringe (SQ form).
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.
06Stack Synergy
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions
PT-141
— no documented stacks